Study on serum erythropoietin levels in patients with hematologic malignancies.
- Author:
Bing HAN
1
;
Yuan-kai SHI
;
Jun ZHU
;
Xiao-hui HE
;
Ning-jing LIN
;
Shu-lan LI
;
Ti SHEN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Anemia, Iron-Deficiency; blood; complications; Enzyme-Linked Immunosorbent Assay; Erythropoietin; blood; Female; Hematologic Neoplasms; blood; complications; Hemoglobins; metabolism; Humans; Male; Middle Aged; Prospective Studies
- From: Chinese Journal of Hematology 2006;27(8):543-545
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study whether hematologic malignancy patients with anemia have a lower erythropoietin (EPO) response.
METHODSSerum EPO levels were detected by ELISA in patients with hematologic malignancies and with iron deficiency anemia (IDA). Eighty patients with hematologic malignancies, including 13 multiple myeloma (MM), 7 chronic lymphocytic leukemia (CLL) and 60 non-Hodgkin's lymphoma (NHL) were studied. Thirty of them had anemia(21 NHL,6 MM and 3 CLL). Twenty patients with IDA were studied as the control.
RESULTSHematologic malignancy patients with anemia had higher EPO levels [(97.8 +/- 183.9) IU/L] than those with normal Hb values [(27.8 +/- 85.4) IU/L; P <0.01]. In patients with IDA, serum EPO response was inversely correlated with Hb level (r= -0.5, P <0.05) , but no such inverse correlation was found in the hematologic malignancy patients with anemia (r = -0.14). After corrected for Hb level, the serum EPO levels were significantly lower in anemic patients with hematologic malignancies than in IDA patients (P = 0.032) , indicating a decreased EPO response in the former group.
CONCLUSIONAnemia associated with hematologic malignancy might result from an inappropriately low EPO response. EPO treatment for these patients may be beneficial.
